Thomas Smith
Stock Analyst at Leerink Partners
(1.96)
# 3,146
Out of 5,130 analysts
61
Total ratings
32.73%
Success rate
6.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Maintains: Outperform | $20 → $32 | $19.56 | +63.60% | 2 | Jan 7, 2026 | |
| EVMN Evommune | Initiates: Outperform | $42 | $20.13 | +108.64% | 1 | Dec 1, 2025 | |
| RAPT RAPT Therapeutics | Upgrades: Outperform | $16 → $37 | $33.62 | +10.05% | 3 | Sep 26, 2025 | |
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $1.14 | -12.28% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $3.60 | +150.00% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $2.64 | +165.15% | 7 | Nov 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $8.20 | +375.61% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $6.21 | +318.68% | 1 | Mar 25, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $114.40 | -82.52% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $788.49 | -44.83% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $78.14 | -53.93% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $2.15 | +225.58% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $26.03 | -19.32% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $31.73 | +41.82% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $11.18 | -46.33% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $5.85 | +2.56% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.66 | +651.99% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $18.49 | -8.06% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $27.38 | +133.75% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $17.60 | +297.73% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $1.73 | +1,402.89% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $31.99 | -62.49% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $20.50 | +1,851.22% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $19.20 | +316.67% | 2 | Dec 8, 2020 |
Alumis
Jan 7, 2026
Maintains: Outperform
Price Target: $20 → $32
Current: $19.56
Upside: +63.60%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $42
Current: $20.13
Upside: +108.64%
RAPT Therapeutics
Sep 26, 2025
Upgrades: Outperform
Price Target: $16 → $37
Current: $33.62
Upside: +10.05%
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $1.14
Upside: -12.28%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $3.60
Upside: +150.00%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $2.64
Upside: +165.15%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $8.20
Upside: +375.61%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $6.21
Upside: +318.68%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $114.40
Upside: -82.52%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $788.49
Upside: -44.83%
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $78.14
Upside: -53.93%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $2.15
Upside: +225.58%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $26.03
Upside: -19.32%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $31.73
Upside: +41.82%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $11.18
Upside: -46.33%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $5.85
Upside: +2.56%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.66
Upside: +651.99%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $18.49
Upside: -8.06%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $27.38
Upside: +133.75%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $17.60
Upside: +297.73%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $1.73
Upside: +1,402.89%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $31.99
Upside: -62.49%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $20.50
Upside: +1,851.22%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $19.20
Upside: +316.67%